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Abstract
Introduction: Type 4 phosphodiesterases (PDE4) play an important role in immune cells through the hydrolysis of the 
second messenger, cAMP. Inhibition of PDE4 has previously been shown to suppress immune and inflammatory 
responses, demonstrating PDE4 to be a valid therapeutic target for immune-mediated pathologies. We assessed the 
anti-inflammatory effects of a novel PDE4 inhibitor, apremilast, in human synovial cells from rheumatoid arthritis (RA) 
patients, as well as two murine models of arthritis.
Methods: Cells liberated from tissue excised from arthritic joints of RA patients were cultured in the presence of 
increasing concentrations of apremilast for 48 hours and spontaneous tumour necrosis factor-alpha (TNFα) production 
was analysed in culture supernatants by ELISA. In addition, arthritis was induced in BALB/c and DBA/1 mice by passive 
transfer of anti-type II collagen mAb and immunisation with type II collagen, respectively. Mice with established 
arthritis received 5 or 25 mg/kg apremilast and disease severity was monitored relative to mice receiving vehicle alone. 
At the end of the study, paws were removed and processed for histopathological assessment. Behavioural effects of 
apremilast, relative to rolipram, were assessed in naïve DBA/1 mice using an automated activity monitor (LABORAS).
Results: Apremilast dose dependently inhibited spontaneous release of TNFα from human rheumatoid synovial 
membrane cultures. Furthermore, apremilast significantly reduced clinical score in both murine models of arthritis over 
a ten day treatment period and maintained a healthy joint architecture in a dose-dependent manner. Importantly, 
unlike rolipram, apremilast demonstrated no adverse behavioural effects in naïve mice.
Conclusions: Apremilast is an orally available PDE4 inhibitor that reduces TNFα production from human synovial cells 
and significantly suppresses experimental arthritis. Apremilast appears to be a potential new agent for the treatment of 
rheumatoid arthritis.
Introduction
There has been significant progress in the treatment of
rheumatoid arthritis (RA), particularly with the develop-
ment of anti-TNFα therapy. The anti- TNFα biologicals
currently in use (infliximab, etanercept and adalimumab)
are highly effective in reducing inflammation and limiting
joint destruction [1,2]. However, this costly treatment is
administered via repeated injections; hence, there is a
need for cheaper, orally available treatments that reduce
the production of TNFα and other inflammatory media-
tors. A much explored pharmacological method to
inhibit TNFα production is via the inhibition of Type 4
phosphodiesterases (PDE4). PDE4 inhibitors are syn-
thetic, small molecular weight compounds that are orally
available and have been demonstrated to reduce TNFα
production in human and mouse lymphocytes and mac-
rophages [3,4].
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There are 11 families in the PDE group, many of which
contain a number of subtypes [5]. PDE4 is a cyclic ade-
nosine monophosphate (cAMP) specific enzyme, which
hydrolyses cAMP to AMP and is the predominant isoen-
zyme expressed in macrophages, lymphocytes and neu-
trophils [6]. Elevation of intracellular cAMP, via
inhibition of PDE4, triggers the protein kinase A pathway,
inhibits TNFα production and suppresses the immune
response [7-9]. Although the anti-inflammatory proper-
ties of PDE4 inhibitors could be exploited for the treat-
ment of an array of inflammatory diseases, no PDE4
inhibitors have been approved for clinical use due to
problems with toxicity [10]. PDE4 was initially chosen as
a target in the treatment of airway inflammation due to
its expression in the airways [11,12]. At present, roflumi-
last [13] is pending regulatory approval for the treatment
of chronic obstructive pulmonary disease (COPD) [14].
Although there are a number of PDE4 inhibitors cur-
rently available to researchers, most induce side effects of
nausea and emesis. Other reported side effects include
headaches, diarrhoea, heart failure and arrhythmias
[15,16]. A novel PDE4 inhibitor, apremilast has recently
been generated [17] which has a half maximal inhibitory
concentration (IC50) of 74 nM and inhibits TNFα produc-
tion from lipopolysaccharide (LPS)-stimulated human
peripheral blood mononuclear cells (PBMC) and whole
blood by 7.7 nM and 11 nM, respectively [17]. Most
recently, apremilast has exhibited broad anti-inflamma-
tory effects in vitro, through the inhibition of multiple
mediators, including TNFα, interferon (IFN)γ, granulo-
cyte macrophage-colony stimulating factor, IL-12 and IL-
23 in LPS-stimulated human monocytes, with similar
effects on TNFα reported in human NK cells and kerati-
nocytes, two cell types involved in psoriasis pathophysi-
ology [18]. Furthermore, during the course of our studies,
apremilast has entered phase II clinical trials for the treat-
ment of psoriasis, psoriatic arthritis (PsA), and other
inflammatory diseases. Out of 168 patients with PsA par-
ticipating in a phase II randomized, double-blind, placebo
controlled, study conducted in North America and
Europe, 44% met the primary endpoint of ACR20
(improvement of symptoms by 20% according to Ameri-
can College of Rheumatology score) after 12 weeks on 20
mg apremilast twice daily compared with 12% of the pla-
cebo group [19]. In addition, the effects of apremilast
have been tested on a small group of patients with severe
plaque-type psoriasis [20]. Fourteen of seventeen patients
demonstrated an improvement in Psoriasis Area and
Severity Index scores. Apremilast has also been reported
to down-regulate intracellular IL-6 in cell lysates of
myeloma cell and human umbilical vein endothelial cells
co cultures [21]. As TNFα blockade is known to be an
exceedingly effective therapeutic approach in many
patients with ankylosing spondylitis, the effects of apre-
milast in ankylosing spondylitis are currently being tested
in a phase II, randomised, double-blinded, clinical control
study at our centre.
Here, we demonstrate that apremilast inhibits sponta-
neous production of TNFα, but not IL-6 or IL-10 from
ex-vivo  cultures of human rheumatoid synovial mem-
branes. Thus, to determine the anti-arthritic capacity of
apremilast, we treated mice with two different forms of
established experimental arthritis. Disease severity was
evaluated throughout, followed by histological assess-
ment of the extent of joint inflammation and erosion at
the end of the treatment period. Our findings show that
apremilast has potent disease-modifying properties, but,
crucially, lacks the behavioural effects exhibited by the
classical PDE4 inhibitor, rolipram.
Materials and methods
LPS-stimulated monocytes
Buffy coats were purchased from the North London
Blood Bank and cells were separated over a density gradi-
ent to obtain a population of PBMCs. The PBMCs were
further separated into lymphocyte, monocyte and granu-
locyte populations by centrifugal elutriation. Monocytes
were plated out in triplicate into a 96-well flat bottom
plate at 1 × 105 cells/well in RPMI containing 5% heat-
inactivated FCS. The monocytes were then treated with
increasing concentrations of apremilast (Celgene Corpo-
ration, Summit, New Jersey, USA), rolipram (Sigma
Aldrich, Dorset, UK) and a vehicle control consisting of
3.3 × 10-4 % dimethyl sulphoxide (DMSO), the diluent for
the highest concentration of drug, for 30 minutes. The
pre-treated cells were then stimulated with 10 ng/ml LPS
and cultured for 24 hours at 37°C and 5% carbon dioxide.
Cytokines in cell culture supernatants was determined by
ELISA (BD Pharmingen, San Diego, CA, USA), following
the manufacturers' instructions. Absorbance was read
and analysed at 450 nm on a spectrophotometric ELISA
plate reader (Labsystems Multiskan Biochromic, Vienna,
VA, USA) using the Ascent version 2.4.2 software (Ther-
moFisher Scientific, Waltham, MA, USA).
Human rheumatoid synovial membrane cell cultures
Human rheumatoid synovial membrane samples were
obtained from RA patients undergoing joint replacement
surgery, following informed consent and anonymisation.
Experiments were performed at KIR, Imperial College
London and approval was obtained from the Riverside
Research Ethics Committee, UK. The samples were
teased apart and dissected into tiny pieces before enzy-
matic digestion with DNase and collagenase (type IV), as
previously described [22,23]. Once isolated, the cells were
plated in a flat-bottomed 96-well plate in triplicate at 1 ×
106 cells/well in RPMI containing 10% heat-inactivated
FCS. Cells were then treated with increasing concentra-McCann et al. Arthritis Research & Therapy 2010, 12:R107
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tions of apremilast, rolipram or a vehicle control consist-
ing of 3.3 × 10-4 % DMSO. As a positive control, cells were
treated with a combination of anti-TNFα mAb and IL-
1RA (both at 10 μg/ml; R&D Systems, Greater Minneap-
olis, MN, USA). The treated cells were cultured for 48
hours at 37°C and 5% carbon dioxide, before supernatants
were harvested and analysed by ELISA, as described
above. Cell viability was assessed by assaying uptake and
metabolism of 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) as previously described
[24].
Induction and assessment of arthritis - mAb-induced 
arthritis
mAb-induced arthritis experiments were carried out by
MD Biosciences/Harlan, Israel. According to the protocol
described by Terato and colleagues [25], collagen mAb-
induced arthritis was achieved by initial injection of a
four-component arthritogenic mAb cocktail and the sub-
sequent administration of LPS. Monoclonal antibodies
were D1, F10, A2 and D8 clones raised against CB11, a
CNBr-generated arthritogenic fragment of chick type II
collagen. On day 0, six-week-old male BALB/c mice were
given a single intravenous injection of mAb cocktail at a
dose of 100 mg/kg (about 2 mg/mouse). Three days later,
mice received an intraperitoneal injection of 2.5 mg/kg
LPS (about 50 μg/mouse). One hour prior to administra-
tion of LPS, apremilast or vehicle alone (0.5% carboxym-
ethyl cellulose, 0.25% Tween 80) was administered by oral
gavage, and then daily for four days until day 7. Arthritis
was monitored in each animal by measuring paw thick-
ness with micro-calipers and by applying the following
clinical scoring system according to the in-house scale of
Morwell MD Biosciences Inc. (Nes-Ziona, Israel): 0, nor-
mal; 1, mild swelling and redness restricted to digits; 2,
moderate swelling and redness of ankle; 3, severe redness
and swelling of the entire paw including digits; 4, maxi-
mally inflamed limb with involvement of multiple joints,
until day 9 when mice were sacrificed. Hind paws, includ-
ing ankle joints, were removed and processed for paraffin
wax embedding and histology. This study was approved
by the Committee for Ethical Conduct in the Care and
use of Laboratory animals of the Hebrew University, Jeru-
salem.
Induction and assessment of arthritis - collagen-induced 
arthritis
Collagen-induced arthritis (CIA) experiments were per-
formed at KIR, Imperial College London. Ten-week-old
male DBA/1 mice were immunised by intradermal injec-
tion at the base of the tail with 200 μg bovine type II col-
lagen (2 mg/ml) in complete Freund's adjuvant (CFA)
[26]. When mice began to develop signs of arthritis, treat-
ment with apremilast or vehicle (0.5% carboxymethyl cel-
lulose, 0.25% Tween 80) was initiated. Mice were treated
daily by intraperitoneal (i.p.) injection for 10 days post
onset, and disease severity was monitored throughout,
according to the following score: 0, normal, 1, slight
swelling and/or erythema, 2, pronounced oedematous
swelling. At the end of the study, paws were removed and
processed for histological assessment. All procedures
were approved by the Ethical Review Process Committee
and the UK Home Office.
Histopathological assessment of joints
Joints were fixed in 10% neutral buffered formalin for one
week, then transferred into buffered inorganic acid for
decalcification for 48 hours, and then back into 10% for-
malin prior to storage. Joints were trimmed and embed-
ded in paraffin and sections of 6 μm were cut and stained
in H&E. Histopathological changes in the joints from
mAb-induced arthritis were described and scored, using
semi-quantitative grading of five scores (0, unremarkable,
1, minimal, 2, mild, 3, moderate, 4, marked). CIA was
scored as follows: 0, normal; 1, minimal synovitis without
cartilage/bone erosion; 2, synovitis with some marginal
erosion but joint architecture maintained; 3, severe syno-
vitis and erosion with loss of normal joint architecture.
Assessment of spontaneous behaviour using LABORAS
The Laboratory Animal Behaviour Observation, Regis-
tration and Analysis System, (LABORAS, Metris B.V.,
Hoofddorp, The Netherlands), is an automated system
that detects vibrations evoked by movement of a single
rodent in a cage. Pattern recognition software is used to
recognise and quantify different behaviours, including
grooming, mobility, climbing and immobility [27]. Spon-
taneous behaviour of naive mice treated with apremilast
(25 mg/kg i.p), rolipram (25 mg/kg i.p.) or vehicle alone
was assessed for 30 minutes, one hour after dosing, using
LABORAS as described [28]. The time spent engaging in
specified activities or immobility was measured. Animals
were acclimatised to the equipment on two occasions
prior to measurement.
Lymph node cultures
Inguinal lymph nodes from bCII immunised DBA/1 mice
were excised at day 14 post immunisation and cells were
dissociated and plated out in a U bottom 96-well plate at
2 × 106 cells/ml in RPMI 1640 containing 10% fetal bovine
serum, 50 U/ml penicillin/streptomycin and 50 μM 2-
mercaptoethanol. Cells were stimulated with 100 ng/ml
anti-CD3 mAb (145-2C11) or 50 μg/ml bCII, or left
unstimulated. Cells were cultured for 48 hours before 100
μl of supernatant was removed for subsequent cytokine
analysis by ELISA and the remainder was pulsed with 1
μCi per well with 3H-thymidine to measure proliferation.McCann et al. Arthritis Research & Therapy 2010, 12:R107
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Pulsed cells were cultured for a further 20 hours before
thymidine incorporation was measured.
Statistical analysis
Two-way analysis of variance (ANOVA), followed by
Bonferroni multiple comparison test was employed for
analysis of paw thickness on days post onset of arthritis,
spontaneous behaviour in LABORAS and in vitro
cytokine production and proliferation of lymph node cul-
tures. All other data was analysed by one-way ANOVA
followed by Dunnett's multiple comparison test. Calcula-
tions were made using GraphPad Prism software.
MAb-induced arthritis experiments were carried out at
MD Biosciences (Harlan, Israel). All other experiments
were performed at KIR, Imperial College London.
Results and discussion
T o  d a t e ,  s e v e r a l  P D E 4  i n h i b i t o r s  h a v e  b e e n  t e s t e d  i n
experimental arthritis due to their potent capacity to
inhibit TNFα production in a range of cell types
[3,4,12,29,30]. Previously, our group and others have
demonstrated the anti-arthritic effects of PDE4 inhibitors
in experimental arthritis [31-34]. More recently, Yama-
moto and colleagues [35] has reported that a dual PDE7/
PDE4 inhibitor, YM-393059, effectively ameliorates CIA.
During the course of our studies, significant progress has
been made with the second-generation PDE4 inhibitor
roflumilast, now proving effective in clinical trials for
asthma and COPD. Presently, there is no clinical data
available for PDE4 inhibitors in the treatment of RA.
Here, having established that the novel PDE4 inhibitor
apremilast dose dependently inhibits TNFα release from
LPS-stimulated monocytes and rheumatoid synovial
membrane cultures, we next evaluated its anti-arthritic
potential in two independently executed, acute mouse
models of arthritis, namely mAb-induced arthritis and
CIA. Both models have been extensively used in pre-clin-
ical trials, demonstrating high degrees of similarity, in
terms of cellular and humoral-mediated immunity to RA
[36].
Apremilast inhibits TNFα production by LPS-stimulated 
monocytes, and the spontaneous release of TNFα from 
human rheumatoid synovial membrane cultures
It has been previously shown that TNFα production from
LPS-stimulated human monocytes can be inhibited by
PDE4 inhibitors [37]. We demonstrate that apremilast
and rolipram inhibit TNFα production from LPS-stimu-
lated human monocytes that have been cultured for 24
hours, in a dose-dependent manner with IC50s of 55 nM
and 40 nM, respectively (Figure 1a). Data are representa-
tive of three experiments from different donors, all of
which displayed a similar dose-dependent inhibition of
TNFα by apremilast and rolipram. Addition of DMSO
alone (vehicle control) prior to LPS stimulation of human
monocytes increased TNFα production in this experi-
ment; however, this was not consistently observed in all
donors. Human rheumatoid synovial membrane cells
were cultured for 48 hours and spontaneously produced
255.4 ± 37.5 pg/ml, 454.32 ± 81.6 ng/ml and 56.52 ± 9.9
pg/ml of TNFα, IL-6 and IL-10, respectively (mean ±
standard error of the mean). As for the LPS-stimulated
monocytes, these cultures were treated with concentra-
tions of apremilast and rolipram ranging from 6.25 nM to
100 nM. As a positive control, cells were treated with a
combination of anti-TNFα mAb and IL-1RA (both at 10
μg/ml; R&D Systems, Greater Minneapolis, MN, USA).
Apremilast inhibited spontaneous TNFα production in a
dose-dependent manner but did not achieve 50% inhibi-
tion, with a maximal inhibition of 46% at the highest dose
of 100 nM being reached. Rolipram also inhibited TNFα
release in a dose-dependent manner and achieved an
inhibition of 52% at a dose of 100 nM (Figure 1b). Both
IL-6 (Figure 1c) and IL-10 (Figure 1d) was unaffected by
apremilast and rolipram. The effect of apremilast on IL-
1β production in RA synovial membranes was not
assayed here; however, Schafer and colleagues have
recently reported that apremilast does not inhibit IL-1β
production in LPS-stimulated human PBMC at concen-
trations up to 10 μM [18]. The inhibition of spontaneous
TNFα production in human rheumatoid synovial mem-
brane cultures by apremilast and rolipram was not due to
cell death. MTT assays were performed on all cell cul-
tures after the supernatants had been collected and nei-
ther inhibitor had any effect on cell viability [See
Supplementary figure S1 in Additional file 1]. In accor-
dance with our findings, several other PDE4 inhibitors
have been reported to have minimal effects on IL-6 in
human PBMC, while potently inhibiting both TNFα and
IL-1β production [35,38,39]. Similarly, elevation of intra-
cellular cAMP by the addition of up to 1 mM dibutyryl
cAMP to RA synovial membrane cultures had no effect
on spontaneous production of IL-10 [40].
Apremilast reduces severity of mAb-induced arthritis in 
BALB/c mice
Arthritis was induced in six-week-old male BALB/c mice
by intravenous administration of a cocktail of four anti-
collagen antibodies, followed by LPS (i.p) three days later.
At this time, mice (eight per treatment) were given a daily,
oral dose of vehicle or dexamethasone, to form negative
and positive control groups, respectively, while experi-
mental groups were treated orally (oral gavage) with 1, 5
or 25 mg/kg apremilast. Treatment continued for four
successive days, until day 7, with close monitoring of dis-
ease severity throughout until day 9 (Figure 2). Two daysMcCann et al. Arthritis Research & Therapy 2010, 12:R107
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after LPS administration (day 5 post injection of mAbs),
all mice began to show varying degrees of arthritis sever-
ity. Apremilast at 5 and 25 mg/kg and dexamethasone at 1
mg/kg, significantly suppressed arthritis severity, as mea-
sured by clinical score (Figures 2a and 2b) and/or paw
thickness (Figure 2c). Statistical significance of the clini-
cal score of individual mice in all treatment groups rela-
tive to vehicle control, over the course of the treatment
period, was assessed by measuring area under the curve
per mouse, followed by one-way ANOVA and then Dun-
nett's multiple comparison test (Figure 2b). Similar to
dexamethasone, the 25 mg/kg apremilast treatment
group reached statistical significance (P < 0.001). Doses
of 1 and 5 mg/kg did not reduce clinical score. On day 6, 7
and 9 post onset, hind paw thickness of mice treated with
25 mg/kg apremilast were significantly less than those
r ec e i vi n g  v e h i c l e .  I t  is  a l so  n o t a b l e  t h a t  o n  da y  9  pos t
onset, at the end of the treatment period, the 5 mg/kg
treatment group also exhibited significantly less paw
thickness relative to vehicle-treated mice (P  < 0.001).
Apremilast 1 mg/kg had no effect on paw swelling (data
not shown), and as expected, dexamethasone completely
abolished paw swelling throughout.
At the end of the experiment, hind paws including the
ankle of each animal were removed and the tibio-tarsal
joint was trimmed longitudinally, before processing for
H&E staining to visualise the extent of inflammation and
joint damage. Histopathological changes in the joints
were described and scored, as detailed in materials and
methods. Scores from the parameters assessed are
described in Table 1. Although the majority of vehicle-
treated mice scored mild or moderate for most parame-
ters, such as pannus formation and cartilage disruption,
apremilast-treated joints were evaluated as unremarkable
or normal throughout. Figure 2d shows a representative
longitudinal section through the tibio-tarsal joint of a
vehicle and apremilast (25 mg/kg) treated mouse. Moder-
ate inflammation of the synovial membrane (asterisk) is
Figure 1 Apremilast inhibits TNFα release from LPS-stimulated monocytes and human rheumatoid synovial membrane cultures. Human 
peripheral blood monocytes were treated with increasing concentrations of apremilast, 30 minutes before stimulating with 10 ng/ml lipopolysaccha-
ride (LPS) for 24 hours. (a) Culture supernatants were assayed for TNFα by ELISA. Data is representative of three donors. Human rheumatoid arthritis 
(RA) synovial membrane cells were cultured for 48 hours in the presence of apremilast, rolipram or controls and spontaneous production of (b) TNFα, 
(c) IL-6 and (d) IL-10 in culture supernatants was measured by ELISA. Means and standard errors of percent inhibition, from five (apremilast) or two 
(rolipram) donors are plotted. As a positive control, cells were treated with a combination of anti-TNFα mAb and IL-1RA. Statistical analysis was calcu-
lated by one-way analysis of variance and Dunnett's multiple comparison test. Each test group was compared to (a) cells + LPS, or (b to d) cells only. * 
P < 0.05, ** P < 0.01, *** P < 0.001.
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Figure 2 Apremilast reduces severity of mAb-induced arthritis in BALB/c mice. (a) Arthritic mice were treated orally with apremilast, dexame-
thasone or vehicle and disease severity was evaluated and assigned a clinical score. (b) Area under the curve for each mouse was calculated and sta-
tistical significance relative to vehicle control group was analysed (*** P < 0.001). (c) Paw thickness was measured throughout with microcalipers and 
statistical significance was calculated by two-way analysis of variance with Bonferroni post test analysis. Means and standard error of the mean are 
plotted, eight mice per group (*** P < 0.001). H&E staining of a longitudinal section through the tibio-tarsal joint from a vehicle-treated mouse and 
one treated with 25 mg/kg apremilast is shown in (d). Asterisk shows inflammation of the synovial membrane, small arrow, erosion of articular carti-
lage, and bold arrow, fibrin deposits and inflammatory cell infiltrate within the articular cavity. Images were acquired at 100 × magnification.
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Table 1: Histopathological features observed in the tibio-tarsal joint of arthritic mice treated with vehicle or 25 mg/kg 
apremilast
Vehicle Apremilast
A n i m a l  # 1234567812345678
S y n o v i a l  h y p e r p l a s i a 1212211100000000
S y n o v i a l  v i l l u s  f o r m a t i o n 1212211100000000
F i b r i n  d e p o s i t i o n 2333323300000101
I n f l a m m a t o r y  i n f i l t r a t e  i n  t h e  s y n o v i a l  m e m b r a n e 3333333300000000
P a n n u s  f o r m a t i o n 3333333300000000
C a r t i l a g e  d i s r u p t i o n 2222222300000000
H y a l i n e  c a r t i l a g e  d e s t r u c t i o n 2222222300000000
S u b c h o n d r a l  b o n e  d e s t r u c t i o n 3323222300000000
O v e r a l l  a s s e s s m e n t :  " d e t e r m i n e d  a s  a r t h r i t i s " 3333333300000000
Histopathological changes in the joints from mAb-induced arthritis were described and scored, using semi-quantitative grading of five scores (0, 
unremarkable, 1, minimal, 2, mild, 3, moderate, 4, marked).McCann et al. Arthritis Research & Therapy 2010, 12:R107
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observed in the section from the vehicle-treated mouse
(Figure 2d). Erosion of articular cartilage (small arrow) as
well as fibrin deposits and inflammatory cell infiltrate
within the articular cavity (bold arrow) is also evident. In
contrast, there is no apparent inflammation of the tibio-
tarsal joint from the mouse treated with 25 mg/kg apre-
milast, and the joint architecture has remained intact,
similar to that of a healthy, non-arthritic mouse.
Apremilast reduces severity of CIA in DBA/1 mice
The therapeutic effectiveness of apremilast in suppress-
ing experimental arthritis was evaluated further in CIA; a
well-established model of murine arthritis involving a
s i n g l e  i m m u n i s a t i o n  o f  m a l e  D BA / 1  m i c e  wi t h  t ype  II
bovine collagen in CFA (Figure 3). Fourteen mice per
treatment group were given a daily, oral administration of
vehicle, or 5 or 25 mg/kg apremilast from day one of
onset, to day 10 post onset of arthritis and disease sever-
ity was evaluated throughout by means of semi-quantita-
tive clinical score as described in materials and methods.
The change in clinical score from day 1 post onset is plot-
ted in Figure 3a. Clinical scores of all mice were compara-
ble (0.5 or 1) when treatment was initiated. Although
both doses of apremilast-suppressed arthritis, relative to
vehicle, it was clear that the higher dose had a more pro-
found effect. The area under the curve of Δclinical score
for each mouse was calculated and statistical significance,
relative to vehicle control group, was evaluated (Figure
3b). In accordance with apremilast treatment in mAb-
induced arthritis, Δclinical score of mice receiving 25 mg/
kg but not 5 mg/kg apremilast was significantly reduced,
as compared with those given vehicle only (P < 0.01).
In order to assess joint pathology, the affected hind
paws of each animal was removed at the end of the exper-
Figure 3 Apremilast reduces severity of collagen-induced arthritis in DBA/1 mice. Arthritic, male DBA/1 mice were treated from day one of on-
set to day 10 post onset of arthritis with a daily, intra-peritoneal dose of apremilast or vehicle, after which the mice were sacrificed and paws were 
removed for histological analysis. Disease severity was evaluated throughout. Change in clinical score is plotted in (a). Each treatment group com-
prised of 14 mice, with means and standard errors plotted. (b) The statistical significance of the clinical score of apremilast-treated compared with 
vehicle-treated mice was calculated from area under the curve (AUC) for each mouse over the 10 day treatment period (* P < 0.05). Representative 
images of H&E-stained sections through the proximal interphalangeal joint of an apremilast-treated mouse and a vehicle-treated mouse are shown 
(c). Scale bars are 500 μm. (d) All sections were scored for the extent of inflammation and damage, and graded accordingly. (* P < 0.05).
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iment and processed for H&E staining. Representative
images of H&E-stained sections through the proximal
inter-phalangeal joint of a vehicle-treated and an apremi-
last-treated mouse are shown in Figure 3c. Although the
joint of the vehicle-treated mouse is clearly flooded with
inflammatory cell infiltrate and displays severe loss of
architecture, the joint from the apremilast-treated mouse
shows a clear joint space and normal joint architecture
with articular cartilage and bone preserved. Sections
from proximal inter-phalangeal joints from treated mice
were graded according to the parameters detailed in
materials and methods. Interestingly, sections from both
apremilast treatment groups (5 and 25 mg/kg) displayed
significantly reduced joint pathology relative to those
from vehicle-control mice (P  < 0.05, Figure 3d).
Apremilast lacks adverse effects of rolipram
I t  i s  w e l l  d o c u m e n t e d  t h a t  P D E 4  i n h i b i t o r s ,  i n c l u d i n g
rolipram, can induce a variety of side effects ranging from
nausea, vomiting and diarrhoea, to more serious condi-
tions such as vasculitis and colitis (reviewed in [15]). In
mice, the main effect we observed following treatment
with rolipram is lethargy. To determine whether apremi-
last triggers similar side effects, treated mice were moni-
tored using an automated activity monitor (LABORAS)
to assess multiple activities including immobility, groom-
ing (Figure 4a), climbing and locomotion (Figure 4b)
[27,28,41]. Strikingly, mice treated with 25 mg/kg apremi-
last (i.p.) did not show any significant behavioural
changes in any of the parameters tested. As predicted,
mice treated with rolipram (i.p.) exhibited significantly
increased immobility (P  < 0.001), reduced grooming
(although not statistically significant) and reduced loco-
motion (P < 0.05); factors associated with lethargy (n = 8
per group). Means and standard errors are plotted. Nota-
bly, mice treated with either apremilast or rolipram did
not experience diarrhoea or significant weight loss. Thus,
we conclude that, unlike rolipram, apremilast does not
influence spontaneous behaviour and lethargy at a dose
that ameliorates CIA and suppresses inflammation.
Apremilast inhibits antigen-specific T cell cytokine 
production and proliferation
Lymph node cultures from male DBA/1 mice immunised
with bCII in CFA were unstimulated, or stimulated with
bCII or anti-CD3 mAb, in the presence of increasing con-
centrations of apremilast or 100 μM rolipram, (used as
positive control only), for three days. After 48 hours,
supernatants were collected for cytokine analysis, before
cells were pulsed with tritiated thymidine to measure
proliferation (Figure 5). All concentrations of apremilast
and rolipram significantly inhibited unstimulated, anti-
gen-specific, as well as total, T cell production of TNFα
(Figure 5a) and IFNγ (Figure 5b; P < 0.001). Furthermore,
antigen-specific T cell proliferation was significantly
inhibited in a dose-dependent manner, while only rolip-
ram inhibited total T cell proliferation, as observed in
anti-CD3 mAb-stimulated lymph node cultures (Figure
5c). No cytotoxic effects of apremilast were observed in
lymph node cultures when routinely assayed by MTT
(data not shown).
Conclusions
Apremilast is a novel, orally available PDE4 inhibitor that
inhibits spontaneous TNFα production from human
rheumatoid synovial membrane cultures, ex-vivo, with
Figure 4 The effect of 25 mg/kg apremilast or rolipram on spontaneous behaviour was tested on naïve mice using LABORAS automated 
activity monitor. The average time spent (a) immobile and grooming and (b) climbing and during locomotion are plotted. n = 8 per group, * P < 
0.05, *** P < 0.001, relative to vehicle treatment. Mice were monitored for 30 minutes, one hour after receiving treatment. n.s., not significant.
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similar efficacy to rolipram. In addition, apremilast effec-
tively reduced the severity of both mAb-induced arthritis
and CIA in BALB/c and DBA/1 mice, respectively, over
10 days post onset, without any evident side effects, often
associated with classical PDE4 inhibitors such as rolip-
ram. Taken together, our results show that apremilast has
therapeutic potential for the treatment of RA and other
chronic inflammatory conditions where TNFα plays a
major pathological role.
Additional material
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Additional file 1 Supplementary figure S1. Apremilast has no effect 
on cell viability in human cells. (a) Human monocytes and (b) rheuma-
toid arthritis (RA) synovial membrane cells were cultured with increasing 
concentrations of apremilast or rolipram as in Figure 1. After supernatants 
were collected for cytokine analysis, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) was added at a final concentration of 0.5 ng/
ml for six hours. A 100 μl sample of 10% SDS in 0.01 M HCl was then added 
overnight before the plate was read on a spectrophotometer at 620 nm. 
None of the culture conditions assayed altered cell viability relative to cells 
alone.
Figure 5 Apremilast inhibits antigen specific T cell cytokine production and proliferation in lymph node cultures. Male DBA/1 mice were im-
munised with bCII in CFA and 14 days later, inguinal lymph nodes were removed and cells were dissociated. Lymph node cultures, unstimulated, or 
stimulated with either bCII or anti-CD3 mAb, were cultured in the presence of increasing concentrations of apremilast or 100 μM rolipram for 48 hours 
at which time supernatants were removed and analysed for (a) TNFα, and (b) interferon (IFN)γ production by ELISA. (c) Cells were then pulsed with 
3H- thymidine for a further 20 hours to assess cell proliferation. Statistical significance between treatment and control groups was calculated by two-
way analysis of variance with Bonferroni multiple comparison test. (* P < 0.05, *** P < 0.001).
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